Swiss National Bank
NKTR icon

Swiss National Bank’s Nektar Therapeutics NKTR Stock Holding History

Swiss National Bank’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.45M Buy
47,900
+16,000
+50% +$911K ﹤0.01% 1560
2025
Q4 		$1.35M Buy
+31,900
New +$1.79M ﹤0.01% 2044
2023
Q2 		– Sell
-27,047
Closed -$285K – 2639
2023
Q1 		$285K Sell
27,047
-3,120
-10% -$94.4K ﹤0.01% 2614
2022
Q4 		$1.02M Buy
30,167
+720
+2% +$34.8K ﹤0.01% 2332
2022
Q3 		$1.41M Buy
29,447
+354
+1% +$21.1K ﹤0.01% 2114
2022
Q2 		$1.66M Hold
29,093
– – ﹤0.01% 2050
2022
Q1 		$2.35M Buy
29,093
+2,133
+8% +$316K ﹤0.01% 1943
2021
Q4 		$5.46M Buy
26,960
+107
+0.4% +$23.2K ﹤0.01% 1412
2021
Q3 		$7.23M Buy
26,853
+493
+2% +$119K ﹤0.01% 1195
2021
Q2 		$6.79M Sell
26,360
-960
-4% -$266K ﹤0.01% 1272
2021
Q1 		$8.2M Buy
27,320
+353
+1% +$110K 0.01% 1111
2020
Q4 		$6.88M Buy
26,967
+74
+0.3% +$19.1K ﹤0.01% 1155
2020
Q3 		$6.69M Buy
26,893
+713
+3% +$224K 0.01% 1002
2020
Q2 		$9.1M Buy
26,180
+3,433
+15% +$1.07M 0.01% 812
2020
Q1 		$6.09M Buy
22,747
+292
+1% +$90.3K 0.01% 828
2019
Q4 		$7.27M Sell
22,455
-15,920
-41% -$4.62M 0.01% 935
2019
Q3 		$10.5M Buy
38,375
+815
+2% +$299K 0.01% 740
2019
Q2 		$20M Sell
37,560
-940
-2% -$471K 0.02% 583
2019
Q1 		$19.4M Buy
38,500
+1,100
+3% +$652K 0.02% 582
2018
Q4 		$18.4M Buy
37,400
+920
+3% +$555K 0.02% 562
2018
Q3 		$33.4M Buy
36,480
+1,033
+3% +$882K 0.04% 461
2018
Q2 		$26M Buy
35,447
+17,114
+93% +$19.7M 0.03% 535
2018
Q1 		$29.2M Buy
18,333
+580
+3% +$747K 0.04% 487
2017
Q4 		$15.9M Buy
17,753
+453
+3% +$268K 0.02% 616
2017
Q3 		$6.23M Buy
17,300
+247
+1% +$77.3K 0.01% 895
2017
Q2 		$5M Buy
17,053
+260
+2% +$75.1K 0.01% 998
2017
Q1 		$5.91M Buy
16,793
+380
+2% +$85.4K 0.01% 892
2016
Q4 		$3.02M Buy
16,413
+1,753
+12% +$356K ﹤0.01% 1287
2016
Q3 		$3.78M Sell
14,660
-213
-1% -$54.8K 0.01% 1088
2016
Q2 		$3.17M Hold
14,873
– – 0.01% 1169
2016
Q1 		$2.96M Buy
14,873
+3,620
+32% +$695K 0.01% 1183
2015
Q4 		$2.84M Hold
11,253
– – 0.01% 1097
2015
Q3 		$1.85M Buy
11,253
+1,480
+15% +$262K ﹤0.01% 1365
2015
Q2 		$1.83M Buy
9,773
+346
+4% +$59.5K ﹤0.01% 1359
2015
Q1 		$1.55M Buy
9,427
+167
+2% +$34.3K ﹤0.01% 1467
2014
Q4 		$2.15M Buy
9,260
+227
+3% +$48.5K 0.01% 1207
2014
Q3 		$1.64M Sell
9,033
-100
-1% -$19.1K 0.01% 1322
2014
Q2 		$1.76M Hold
9,133
– – 0.01% 1345
2014
Q1 		$1.66M Buy
9,133
+2,713
+42% +$537K 0.01% 1329
2013
Q4 		$1.09M Hold
6,420
– – ﹤0.01% 1445
2013
Q3 		$1.01M Sell
6,420
-340
-5% -$62.9K ﹤0.01% 1438
2013
Q2 		$1.17M Buy
+6,760
New +$1.04M 0.01% 1310

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Swiss National Bank's NKTR Position: Q1 2026 in Review

Swiss National Bank increased its Nektar Therapeutics (NKTR) stake by 50% in Q1 2026, buying an estimated $911K and bringing the position to 47,900 shares worth $3.45M. The position accounts for ﹤0.01% of the portfolio, ranked #1560.

Swiss National Bank first reported a position in NKTR in Q2 2013 and has held it in 42 quarters since. The position peaked at $33.4M in Q3 2018. 215 funds tracked by Wall St. Rank hold NKTR as of Q1 2026.

  • Swiss National Bank held 47,900 shares of Nektar Therapeutics worth $3.45M as of Q1 2026.
  • Swiss National Bank bought 16,000 Nektar Therapeutics shares in Q1 2026, an estimated $911K.
  • Nektar Therapeutics made up ﹤0.01% of Swiss National Bank's portfolio in Q1 2026, its #1560 holding.
  • Swiss National Bank first reported a position in Nektar Therapeutics in Q2 2013 and has held it in 42 quarters since.
  • Swiss National Bank's Nektar Therapeutics position peaked at $33.4M in Q3 2018.
  • 215 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2026.

Based on Swiss National Bank's 13F filing for Q1 2026, filed 7 May 2026.